553P Innovative medicinal products and early access provision: Challenges and opportunities to improve access to care for oncology patients

Abstract

Background: Phase I trials aim at offering new therapeutic opportunities to pretreated patients (pts) while assessing efficacy/safety. Trial enrolment is a two-step process: first, an investigator evaluates the pts' eligibility, then the pt is screened and undergoes new tests. This warrants that pts meet the protocol's criteria, notably 90day survival. We report reasons of screening (scr) failure in pts who were deemed eligible by investigators and their outcome.